MedPath

Whole-Body Cooling for Birth Asphyxia in Term Infants

Phase 3
Completed
Conditions
Infant, Newborn
Hypoxia-Ischemia, Brain
Interventions
Device: Control
Device: Induced hypothermia
Registration Number
NCT00005772
Lead Sponsor
NICHD Neonatal Research Network
Brief Summary

This large multicenter trial tested whether cerebral cooling initiated within 6 hours of birth and continued for 72 hours would reduce the risk of death and moderate to severe neurodevelopmental injury at 18-22 months corrected age. Infants at least 36 weeks gestation with an abnormal blood gas within 1 hour of birth, or a history of an acute perinatal event and a 10-min Apgar score \<5, or continued need for ventilation were screened. Following a neurological exam, those with moderate to severe encephalopathy were randomized to a 72-hour period of total body cooling (cooling blanket, followed by slow re-warming). The study was conducted in two phases: Phase I (20 infants) were examined for the safety of an esophageal temperature of 34-35 C; Phase II (main trial, 200 infants) were evaluated for the safety and efficacy of an esophageal temperature of 33-34 C. Cardio-respiratory, electroencephalograms (EEGs), renal, metabolic, and hematologic status, and esophageal and abdominal skin temperature were monitored during the 72 hours of intervention. Surviving children were given neurodevelopmental examinations at 18-22 months corrected age and again at school age (6-7 years of age).

Detailed Description

Perinatal cerebral hypoxia-ischemia injury is an important cause of death and neurodevelopmental disability. Data from animal models suggest that brain cooling immediately after injury is neuroprotective. Experience with total body cooling during surgery, accidental near drownings, and one Phase I trial of term infants suggest that it is effective and safe in children.

This large multicenter trial tested whether cerebral cooling initiated within 6 hours of birth and continued for 72 hours would reduce the risk of death and moderate to severe neurodevelopmental injury at 18-22 months corrected age. Infants at least 36 weeks gestation with an abnormal blood gas within 1 hour of birth, or a history of an acute perinatal event and a 10-min Apgar score \<5, or continued need for ventilation were screened. Following a neurological exam, those with moderate to severe encephalopathy were randomized to a 72-hour period of total body cooling (cooling blanket, followed by slow re-warming). The study was conducted in two phases: Phase I (20 infants) were examined for the safety of an esophageal temperature of 34-35 C; Phase II (main trial, 200 infants) were evaluated for the safety and efficacy of an esophageal temperature of 33-34 C. Cardio-respiratory, electroencephalograms (EEGs), renal, metabolic, and hematologic status, and esophageal and abdominal skin temperature were monitored during the 72 hours of intervention.

Neurodevelopmental outcome was assessed at 18-22 mos of age by masked certified examiners. The outcome at 18-22 months showed that whole-body cooling reduces the risk of death or moderate to severe disability in infants with hypoxic ischemic encephalopathy.

Surviving infants were assessed at 6-7 years (school age).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
208
Inclusion Criteria
  • At least 36 weeks gestation
  • Any blood gas (cord, postnatal) done within the first 60 minutes had a pH less than or equal to 7.0
  • Any blood gas (cord postnatal) done within the first 60 minutes had a base deficit greater than or equal to 16 mEq/L
  • All infants must have seizures or signs of moderate to severe encephalopathy before randomization
Exclusion Criteria
  • Inability to randomize by 6 hours of age
  • Presence of known chromosomal anomaly or major congenital anomaly
  • Severe intrauterine growth restriction (weight less than 1800g)
  • All blood gases done within the first 60 minutes had a pH less than 7.15 and a base deficit less than 10 mEq/L
  • Infants in extremis for whom no additional intensive therapy will be offered by attending neonatologist
  • Parents refuse consent
  • Attending neonatologist refuses consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
NormothermicControlPlacebo: Normothermic control group (with esophageal temperature at or near 37.0°C) for 96 hours
HypothermiaInduced hypothermiaInduced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours
Primary Outcome Measures
NameTimeMethod
Death or moderate or severe disability18-22 months corrected age
Secondary Outcome Measures
NameTimeMethod
Length of hospital stayUntil discharge
Post-neonatal deaths18-22 months corrected age
Frequency of multi-organ dysfunctionUntil discharge
Withdrawal of supportUntil discharge
Multiple disability18-22 months corrected age
Seizure disorders18-22 months corrected age
Rehospitalizations18-22 months corrected age

Trial Locations

Locations (16)

Harvard University

🇺🇸

Cambridge, Massachusetts, United States

Wayne State University

🇺🇸

Detroit, Michigan, United States

RTI International

🇺🇸

Durham, North Carolina, United States

Cincinnati Children's Medical Center

🇺🇸

Cincinnati, Ohio, United States

Emory University

🇺🇸

Atlanta, Georgia, United States

Indiana University

🇺🇸

Indianapolis, Indiana, United States

Case Western Reserve University, Rainbow Babies and Children's Hospital

🇺🇸

Cleveland, Ohio, United States

University of Texas Southwestern Medical Center at Dallas

🇺🇸

Dallas, Texas, United States

University of Texas Health Science Center at Houston

🇺🇸

Houston, Texas, United States

University of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

Stanford University

🇺🇸

Palo Alto, California, United States

Yale University

🇺🇸

New Haven, Connecticut, United States

University of New Mexico

🇺🇸

Albuquerque, New Mexico, United States

University of Miami

🇺🇸

Miami, Florida, United States

University of Tennessee

🇺🇸

Memphis, Tennessee, United States

Brown University, Women & Infants Hospital of Rhode Island

🇺🇸

Providence, Rhode Island, United States

© Copyright 2025. All Rights Reserved by MedPath